Technavio Announces Top Three Trends for the Infectious Disease Treatment Market in China Through 2020

LONDON--()--Technavio’s latest infectious disease treatment market in China report highlights three key emerging trends predicted to impel market growth through 2020. Technavio defines an emerging trend as something that has potential for significant impact on the market and contributes to its growth or decline.

There are 3,000-5,000 local drug manufacturers in China, generating sales of USD 5 million-USD 10 million annually, with approximately 70% of their revenue from the sales of drugs to tier 1 hospitals. Local companies develop cost-effective products to gain market shares. Healthcare reforms that aim to decrease the disparity between urban and rural access to healthcare provide huge opportunities for local manufacturers to increase their market presence in the region.

“The anticipated approval of drugs is expected to fuel the market. Some drugs that are under review by the SFDA include oral IFN-free regimens such as Sovaldi and Harvoni. Combination therapies under clinical trials include ceftolozane and tazobactam therapy; raltegravir and lamivudine fixed-dose combination; and ritonavir, ombitasvir, and dasabuvir therapy,” said Barath Palada, one of Technavio’s lead industry analysts for infectious and rare diseases.

Technavio’s market research study identifies the following three emerging trends expected to propel the infectious disease treatment market in China:

  • Increase in collaborations and M&A
  • Emergence of IFN-free therapies
  • Increase in injection drug users

Increase in collaborations and M&A

The infectious disease treatment market is growing rapidly in terms of collaborative agreements and M&A. The World Bank; and pharmaceutical companies and global health organizations are collaborating to control and altogether eliminate 10 neglected tropical diseases such as dracunculiasis, leprosy, schistosomiasis, lymphatic filariasis, HIV/acquired immunodeficiency syndrome (AIDS), tuberculosis and malaria by the end of 2020. These collaborations are intended to reduce the prevalence of infectious diseases, especially in developing and emerging countries such as China and India. M&As are intended to increase market penetration of the acquirer or enhance the product portfolio of the parent company. Since 2012, this region is witnessing many mergers that aid this cause. In April 2015, China Jo-Jo Drugstores announced that its subsidiary, Hangzhou Jiuzhou Grand Pharmacy Chain signed a new sales incentive agreement with Wyeth Pharmaceutical Company, a wholly owned subsidiary of Pfizer, in China. Industry experts from Technavio anticipate this trend to continue over the next four years.

Emergence of IFN-free therapies

At present, hepatitis C treatment relies on the administration of IFN-based therapies in combination with ribavirin. Existing therapies are associated with side-effects such as anemia and leukopenia. Owing to this, researchers and vendors are focusing on developing DAAs with minimal side effects. These therapies are intended to be all-oral regimens. Once approved, they will have a positive effect on the market. For instance, Gilead Sciences is investigating Sovaldi, which received priority review approval for Hepatitis C. Sovaldi has achieved blockbuster status in other regions such as the US and the EU. In February 2014, Gilead Sciences submitted a new drug application (NDA) for the combination therapy of sofosbuvir and ledipasvir to the US FDA. The product is awaiting approval in China from regulatory bodies. The launch of these therapies is expected to significantly increase the sales of hepatitis drugs in China during the forecast period.

Increase in injection drug users

Injection drug users purchase drugs in bulk and prepare them for consumption by multiple consumers. Sharing of injection equipment among drug users leads to the transmission of virus from infected drug users to non-infected ones. Misuse of prescription opioids has increased the risk of hepatitis transmission among drug users in China. Thus, increasing drug consumption among adolescents and the youth is increasing the prevalence of hepatitis among this population group, thereby necessitating treatment.

Browse related reports:

Purchase any three reports for the price of one by becoming a Technavio subscriber. Subscribing to Technavio’s reports allows you to download any three reports per month for the price of one. Contact enquiry@technavio.com with your requirements and a link to our subscription platform.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
http://www.technavio.com/
media@technavio.com

Release Summary

Technavio’s latest infectious disease treatment market in China report highlights three key emerging trends predicted to impel market growth through 2020.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
http://www.technavio.com/
media@technavio.com